AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Gastrointestinal disease

exocrine pancreatic carcinoma

A carcinoma that arises from epithelial cells of the exocrine pancreas

🔔 Follow weekly
🧬11589genes / proteins with evidence
💊253drugs and clinical candidates
🧪8recruiting trials worldwide
✅1approved
📈33phase 3
🧬

Understand exocrine pancreatic carcinoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

A carcinoma that arises from epithelial cells of the exocrine pancreas

From the Open Targets disease record ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for exocrine pancreatic carcinoma itself.

🤖

AI briefing

Where the science on exocrine pancreatic carcinoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens exocrine pancreatic carcinoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.81
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.80
PALB2 partner and localizer of BRCA2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.79
SMAD4 SMAD family member 4PROTACsmall molecule🧊 AlphaFold structure ↗ 0.78
BRCA2 BRCA2 DNA repair associatedPROTACsmall molecule🧊 AlphaFold structure ↗ 0.76
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
CDKN2A cyclin dependent kinase inhibitor 2A🧊 AlphaFold structure ↗ 0.73
POLD1 DNA polymerase delta 1, catalytic subunitPROTACsmall molecule🧊 AlphaFold structure ↗ 0.70
BRCA1 BRCA1 DNA repair associatedPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.69
RNF43 ring finger protein 43PROTACantibody🧊 AlphaFold structure ↗ 0.69
ATM ATM serine/threonine kinasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.68
POLE DNA polymerase epsilon, catalytic subunitPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
ARID1A AT-rich interaction domain 1APROTAC🧊 AlphaFold structure ↗ 0.66
TGFBR2 transforming growth factor beta receptor 2PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.63
GNAS GNAS complex locus🧊 AlphaFold structure ↗ 0.62

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to exocrine pancreatic carcinoma, by how far it has got
Approved · 1
Gemcitabine HydrochlorideRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Approved
In phase 2 / 3 · 20
Algenpantucel-LPhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 3
CapecitabineThymidylate synthase inhibitorPhase 3
CelecoxibCyclooxygenase-2 inhibitorPhase 3
CisplatinPhase 3
CurcuminPhase 3
Show all 20
Dalteparin SodiumAntithrombin-III activatorPhase 3
ErlotinibEpidermal growth factor receptor erbB1 inhibitorPhase 3
Erlotinib HydrochlorideEpidermal growth factor receptor erbB1 inhibitorPhase 3
Exatecan MesylatePhase 3
FluorouracilThymidylate synthase inhibitorPhase 3
Folinic AcidPhase 3
G17Dt ImmunogenPhase 3
GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 3
GimeracilDihydropyrimidine dehydrogenase inhibitorPhase 3
IrinotecanDNA topoisomerase I inhibitorPhase 3
Irinotecan HydrochlorideDNA topoisomerase I inhibitorPhase 3
LeucovorinPhase 3
Leucovorin CalciumPhase 3
MasitinibFibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitorPhase 3
Early trials · 20
Aldoxorubicin HydrochloridePhase 1/2
Amg-820Macrophage colony stimulating factor receptor inhibitorPhase 1/2
AntroquinonolPhase 1/2
AvelumabProgrammed cell death 1 ligand 1 otherPhase 1/2
Bms-813160C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 5 antagonistPhase 1/2
CemiplimabProgrammed cell death protein 1 inhibitorPhase 1/2
Show all 20
ConatumumabTumor necrosis factor receptor superfamily member 10B agonistPhase 1/2
Cpi 613Phase 1/2
DalotuzumabInsulin-like growth factor I receptor antagonistPhase 1/2
DomvanalimabT-cell immunoreceptor with Ig and ITIM domains inhibitorPhase 1/2
Efineptakin AlfaPhase 1/2
ErfonrilimabCytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitorPhase 1/2
EvofosfamidePhase 1/2
GalunisertibTGF-beta receptor type I inhibitorPhase 1/2
GanitumabInsulin-like growth factor I receptor antagonistPhase 1/2
IbrilatazarPhase 1/2
IfebemtinibFocal adhesion kinase 1 inhibitorPhase 1/2
Irinotecan SucrosofateDNA topoisomerase I inhibitorPhase 1/2
ItacitinibTyrosine-protein kinase JAK1 inhibitorPhase 1/2
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5 otherPhase 1/2
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy